



# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

**Board Line :** +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Date: 27<sup>th</sup> October 2026

To,  
**The Listing Department**  
**National Stock Exchange of India**  
**Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 051

BSE Scrip Code: 543828  
NSE Trading Symbol: SUDARSHAN  
ISIN: INE00TV01023

Dear Sir/Madam,

**Sub: Meeting of the Board of Directors of the Company scheduled to be held on Thursday, 29<sup>th</sup> October, 2026**


Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 29<sup>th</sup> October, 2026, inter alia, to:

- 1) consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2026.
- 2) consider and approve proposal for raising of funds by way of issue of one or more of instruments comprising of equity shares, convertible securities of any other description or warrants or debt securities, through Private Placement / Preferential Issue / Qualified Institutions Placement or such other methods or combinations thereof and to approve ancillary actions for the above mentioned fund raising, subject to such statutory / regulatory approvals as may be necessary

Further, please note that the Trading Window of the Company shall continue to remain closed until the expiry of 48 hours after the declaration of the financial results for the quarter and half year ended 30<sup>th</sup> September, 2026.

The Company hereby informs that, with effect from 27<sup>th</sup> October 2026, the equity shares of the Company have been migrated from the SME Platform to the Main Board of BSE Limited ("BSE") and have been listed on the Main Board of BSE and the National Stock Exchange of India Limited ("NSE").

Accordingly, the notice of the Board Meeting referred to in this communication was intimated to BSE on 26<sup>th</sup> October 2026, as the Company's equity shares were listed exclusively on the SME Platform of BSE as on that date.



**Regd. Off. :** 301, Aura Biplax, Above Kalyan Jewellers, S.V. Road, Borivali (West), Mumbai - 400092.



# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com) • **Website :** [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

**Board Line :** +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

However, in the interest of good corporate governance and as a matter of prudent corporate practice, the Company is also intimating the aforesaid information to NSE following the listing of its equity shares on the Main Board of NSE with effect from 27<sup>th</sup> October 2026.

Request you to take the same on record.

Thanks & Regards,

For, Sudarshan Pharma Industries Limited

Nirav Shah

Company Secretary & Compliance Officer

